Key Takeaways Alkermes posted Q3 EPS of $0.49, beating estimates, with revenue up 4% year over year to $394.2 million.Sales of Vivitrol, Aristada, and Lybalvi rose 7%, 16%, and 32%, respectively, surpassing expectations.ALKS lifted the 2025 revenue forecast to $1.43 to $1.49B and raised sales outlooks for all three key drugs.Alkermes plc (ALKS) reported earnings from continuing operations of 49 cents per share for the third quarter of 2025, which beat the Zacks Consensus Estimate of 42 cents. The company re ...

Core Insights - Alixorexton demonstrated clinically meaningful and statistically significant improvements in wakefulness in patients with narcolepsy type 1 compared to placebo [1][2][3] - The drug showed robust improvements in patient-reported outcomes related to disease severity, fatigue, and cognition across all doses tested [1][2] - Alixorexton was generally well tolerated, with no serious adverse events reported during the study [1][5] Study Details - The Vibrance-1 phase 2 study involved 92 patients with narcolepsy type 1, randomized to receive alixorexton at doses of 4 mg, 6 mg, or 8 mg, or placebo for six weeks [2][7] - The primary endpoint was the Maintenance of Wakefulness Test (MWT), where alixorexton showed statistically significant improvements in mean sleep latency at week six (p<0.0001) [3][9] - Secondary endpoints included the Epworth Sleepiness Scale (ESS) and weekly cataplexy rates, with significant improvements noted at the 6 mg dose (p=0.005) [9] Patient-Reported Outcomes - Alixorexton led to significant improvements in excessive daytime sleepiness (ESS) (p<0.0001), narcolepsy symptom severity (NSS) (p<0.001), cognitive complaints (BC-CCI) (p<0.0001), and fatigue (PROMIS-Fatigue) (p<0.01) [9] - The study highlighted the breadth of benefits that alixorexton may provide across multiple facets of narcolepsy, addressing persistent symptoms that disrupt daily life [2] Future Developments - Alkermes plans to present detailed results from the Vibrance-1 study at the World Sleep Congress in September 2025 [6] - The company is moving forward with a global phase 3 program for alixorexton in patients with narcolepsy type 1 based on the positive outcomes from the phase 2 study [2][6]